TABLE OF CONTENTS
1 INTRODUCTION 20
1.1 OBJECTIVES OF THE STUDY 20
1.2 MARKET DEFINITION 20
1.3 OVERVIEW OF NASAL SPRAY MARKET 21
1.4 CURRENCY AND PRICING 22
1.5 LIMITATION 22
1.6 MARKETS COVERED 22
2 MARKET SEGMENTATION 25
2.1 MARKETS COVERED 25
2.2 GEOGRAPHIC SCOPE 26
2.3 YEARS CONSIDERED FOR THE STUDY 27
2.4 CURRENCY AND PRICING 27
2.5 RESEARCH METHODOLOGY 28
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 31
2.7 SECONDARY SOURCES 32
2.8 ASSUMPTIONS 32
3 MARKET OVERVIEW 33
3.1 DRIVERS 35
3.1.1 IMPROVING PATIENT COMPLIANCE AND ACCEPTABILITY 35
3.1.2 EFFECTIVENESS OVER OTHER FORMS OF DRUG DELIVERY 36
3.1.3 INCREASE IN INFECTION & ALLERGIC CASES 37
3.2 RESTRAINTS 37
3.2.1 PRODUCT RECALLS 37
3.3 OPPORTUNITIES 38
3.3.1 NEW RISING DEMAND FOR SELF ADMINISTRATIVE DRUG DELIVERY 38
3.3.2 EXPANDING THERAPEUTIC APPLICATIONS FOR NASAL SPRAYS 38
3.4 CHALLENGES 39
3.4.1 REGULATORY HURDLES 39
4 EXECUTIVE SUMMARY 40
5 PREMIUM INSIGHTS 43
?
6 MIDDLE EAST AND AFRICA NASAL SPRAY MARKET, BY PRODUCT TYPE 45
6.1 OVERVIEW 46
6.2 DECONGESTION NASAL SPRAY 48
6.3 SALT WATER SOLUTION/ SALINE NASAL SPRAY 49
6.4 STEROID NASAL SPRAY 51
6.5 OTHERS 52
7 MIDDLE EAST AND AFRICA N ASAL SPRAY MARKET, BY CONTAINER DESIGN 53
7.1 OVERVIEW 54
7.2 PRESSURIZED CANISTERS 56
7.3 PUMP BOTTLES 57
8 MIDDLE EAST AND AFRICA NASAL SPRAY MARKET, BY DOSAGE FORM 58
8.1 OVERVIEW 59
8.2 UNIT/SINGLE DOSE 61
8.3 BI DOSE 63
8.4 MULTI DOSE 64
9 MIDDLE EAST AND AFRICA NASAL SPRAY MARKET, BY THERAPEUTIC CLASS 66
9.1 OVERVIEW 67
9.2 ANTIHISTAMINE 69
9.3 NASAL STEROIDS 71
9.4 MAST CELL INHIBITOR 72
9.5 ANTICHOLINERGIC 73
10 MIDDLE EAST AND AFRICA NASAL SPRAY MARKET, BY APPLICATION 74
10.1 OVERVIEW 75
10.2 ALLERGIC AND NON-ALLERGIC RHINITIS 77
10.3 NASAL CONGESTION 79
10.4 CENTRAL NERVOUS SYSTEM DISORDERS 80
10.5 VACCINATION 81
10.6 OTHERS 82
11 MIDDLE EAST AND AFRICA NASAL SPRAY MARKET, BY PRESCRIPTION MODE 83
11.1 OVERVIEW 84
11.2 PRESCRIPTION BASED 86
11.3 OVER THE COUNTER 87
?
12 MIDDLE EAST AND AFRICA NASAL SPRAY MARKET, BY END USER 89
12.1 OVERVIEW 90
12.2 HOSPITALS 92
12.3 CLINICS 93
12.4 HOME CARE SETTINGS 94
12.5 COMMUNITY HEALTH CARE 95
13 MIDDLE EAST AND AFRICA NASAL SPRAY MARKET, BY GEOGRAPHY 96
13.1 MIDDLE EAST AND AFRICA 96
13.1.1 GROWING PREFERENCES FOR DRUG ADMINISTRATION THROUGH INTRA NASAL ROUTE 96
13.1.2 SOUTH AFRICA 104
13.1.3 EGYPT 105
13.1.4 SAUDI ARABIA 106
13.1.5 UNITED ARAB EMIRATES 107
13.1.6 ISRAEL 107
13.1.7 REST OF MIDDLE EAST & AFRICA 108
14 MIDDLE EAST AND AFRICA NASAL SPRAY MARKET, COMPANY LANDSCAPE 109
14.1 COMPANY SHARE ANALYSIS; MIDDLE EAST AND AFRICA 109
15 COMPANY PROFILE 110
15.1 PFIZER INC. 110
15.1.1 COMPANY OVERVIEW 110
15.1.2 REVENUE ANALYSIS 110
15.1.3 COMPANY SHARE ANALYSIS 111
15.1.4 PRODUCT PORTFOLIO 112
15.1.5 RECENT DEVELOPMENTS 112
15.2 CIPLA INC. 113
15.2.1 COMPANY OVERVIEW 113
15.2.2 REVENUE ANALYSIS 113
15.2.3 COMPANY SHARE ANALYSIS 114
15.2.4 PRODUCT PORTFOLIO 114
15.2.5 RECENT DEVELOPMENTS 115
15.3 BAYER AG 116
15.3.1 COMPANY OVERVIEW 116
15.3.2 REVENUE ANALYSIS 116
15.3.3 COMPANY SHARE ANALYSIS 117
15.3.4 PRODUCT PORTFOLIO 117
15.3.5 RECENT DEVELOPMENTS 117
15.4 INNOVUS PHARMACEUTICALS, INC. 118
15.4.1 COMPANY OVERVIEW 118
15.4.2 REVENUE ANALYSIS 118
15.4.3 COMPANY SHARE ANALYSIS 119
15.4.4 PRODUCT PORTFOLIO 119
15.4.5 RECENT DEVELOPMENTS 119
15.5 GLAXOSMITHKLINE PLC. 120
15.5.1 COMPANY OVERVIEW 120
15.5.2 REVENUE ANALYSIS 120
15.5.3 PRODUCT PORTFOLIO 121
15.5.4 RECENT DEVELOPMENTS 121
15.6 ADAPT PHARMA, INC. 122
15.6.1 COMPANY OVERVIEW 122
15.6.2 GEOGRAPHIC PRESENCE 122
15.6.3 PRODUCT PORTFOLIO 123
15.6.4 RECENT DEVELOPMENTS 123
15.7 AISHWARYA GROUP 124
15.7.1 COMPANY OVERVIEW 124
15.7.2 PRODUCT PORTFOLIO 124
15.7.3 RECENT DEVELOPMENTS 124
15.8 ALLERGAN 125
15.8.1 COMPANY OVERVIEW 125
15.8.2 REVENUE ANALYSIS 125
15.8.3 PRODUCT PORTFOLIO 125
15.8.4 RECENT DEVELOPMENTS 126
15.9 ARIUS FORMULATIONS PVT LTD 127
15.9.1 COMPANY OVERVIEW 127
15.9.2 PRODUCT PORTFOLIO 127
15.9.3 RECENT DEVELOPMENTS 127
15.10 AURENA 128
15.10.1 COMPANY OVERVIEW 128
15.10.2 GEOGRAPHIC PRESENCE 128
15.10.3 PRODUCT PORTFOLIO 129
15.10.4 RECENT DEVELOPMENTS 129
15.11 CATALENT, INC 130
15.11.1 COMPANY OVERVIEW 130
15.11.2 REVENUE ANALYSIS 130
15.11.3 PRODUCT PORTFOLIO 131
15.11.4 RECENT DEVELOPMENTS 131
15.12 EGALET CORPORATION 132
15.12.1 COMPANY OVERVIEW 132
15.12.2 REVENUE ANALYSIS 132
15.12.3 PRODUCT PORTFOLIO 133
15.12.4 RECENT DEVELOPMENTS 133
15.13 J PHARMACEUTICALS 134
15.13.1 COMPANY OVERVIEW 134
15.13.2 PRODUCT PORTFOLIO 134
15.13.3 RECENT DEVELOPMENTS 134
15.14 LEEFORD HEALTHCARE LTD 135
15.14.1 COMPANY OVERVIEW 135
15.14.2 GEOGRAPHIC PRESENCE 135
15.14.3 PRODUCT PORTFOLIO 136
15.14.4 RECENT DEVELOPMENTS 136
15.15 MYLAN N.V. 137
15.15.1 REVENUE ANALYSIS 137
15.15.2 PRODUCT PORTFOLIO 138
15.15.3 RECENT DEVELOPMENTS 138
15.16 SANDOZ INTERNATIONAL GMBH 139
15.16.1 COMPANY OVERVIEW 139
15.16.2 GEOGRAPHIC PRESENCE 139
15.16.3 PRODUCT PORTFOLIO 140
15.16.4 RECENT DEVELOPMENTS 140
15.17 ST. RENATUS 141
15.17.1 COMPANY OVERVIEW 141
15.17.2 PRODUCT PORTFOLIO 141
15.17.3 RECENT DEVELOPMENTS 141
15.18 TEVA PHARMACEUTICAL INDUSTRIES LTD. 142
15.18.1 COMPANY OVERVIEW 142
15.18.2 REVENUE ANALYSIS 142
15.18.3 PRODUCT PORTFOLIO 143
15.18.4 RECENT DEVELOPMENTS 143
15.19 ULTRATECH INDIA LIMITED 144
15.19.1 COMPANY OVERVIEW 144
15.19.2 PRODUCT PORTFOLIO 144
15.19.3 RECENT DEVELOPMENTS 144
16 RELATED REPORTS 145